邻甲苯海明 T68599

Product Introduction
Bioactivity


英文名: Orphenadrine

描述: Orphenadrine 是一种非竞争性的 N-甲基-D-天冬氨酸（NMDA）受体拮抗剂，以浓度依赖性方式抑制克隆的 HERG 通道，在 HEK 细胞中产生0.85μM 的 IC。Orphenadrine 是中枢和外周毒蕈碱受体的拮抗剂，通过孔残基 Y652或 F656突变阻断衰减。 Orphenadrine 具有抗痉挛、镇痛和抗胆碱能活性，对在体外和体内对谷氨酸神经毒性具有保护作用。Orphenadrine 对钠离子通道具有抑制作用，可用来治疗帕金森。

体外活性: Orphenadrine decreased CYP2B6 marker activity up to 45-57% in human liver microsomes and up to 80-97% in cell microsomes containing cDNA-expressed CYP2B6. Orphenadrine strongly decreased CYP2D6 marker activity by 80-90%. Orphenadrine also partially decreased the CYP1A2, CYP2A6, CYP3A4, and CYP2C19 marker activities.[4]

体内活性: Orphenadrine (75 mg/kg/day; i.p.; for 3 days) was associated with a 2-fold induction of total hepatic P-450, a 5- and 2.4-fold induction of androstenedione 16 beta- and 6 beta-hydroxylase activity, respectively, and formation of an orphenadrine-P-450 MI complex. Western blots of orphenadrine-induced microsomes revealed a 20-fold increase in P-450 PB-B/D-immunoreactive protein.[2]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (185.61 mM)


关键字: Orphenadrine

相关产品: PF 04531083 | Oxybuprocaine hydrochloride | λ-Cyhalothrin | Halazone | Tolperisone hydrochloride | NHE3-IN-1 | 20(S)-Ginsenoside Rg3 | Rufinamide | GsAF-II | Pilsicainide HCl

相关库: Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | FDA-Approved & Pharmacopeia Drug Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Neuronal Signaling Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library

邻甲苯海明 T68599信息由TargetMol中国为您提供，如您想了解更多关于邻甲苯海明 T68599报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途